Clarus Builds Investment Team

Feb 10 2006 | 10:18pm ET

Clarus Ventures, a global life sciences venture capital firm with offices in San Francisco and Cambridge, Mass., has filled out its investment team to manage its first fund, which closed in December with $500 million in committed capital. The firm has hired three principals and a controller to help manage the fund and Robert Liptak, managing director, said the firm is looking to make one additional hire.

The newly-formed team includes Emmett Cunningham, Michele Park and Scott Requadt, who have joined the firm as principals, and Danielle Bechard, who has joined as controller.

Prior to joining the firm's San Francisco office, Cunningham was senior vice president of medical strategy at Eyetech Pharmaceuticals, where he played a leadership role in the development and approval of Macugen, a drug used to help age-related macular degeneration.

Park joins the San Francisco office of Clarus from Credit Suisse First Boston, where she was an analyst covering large, medium and small capitalization biotechnology companies with a focus on companies with oncologic and anti-infective products.

Requadt joins the Cambridge office from TransForm Pharmaceuticals, where he was director of business development.

Finally, Bechard joins the Cambridge office from the McDonald's Corporation, where she was responsible for franchisee analysis.

The fund will invest in predominantly later-stage biotechnology firms, Liptak said.


In Depth

Part II: Roubini Talks Risk, Recovery And The Threat Of A Triple Dip Recession

Oct 21 2014 | 12:41pm ET

In the second half of our interview with Nouriel Roubini, FINalternatives editor...

Lifestyle

Balyasny Pays Over $6M For Lakefront House

Oct 22 2014 | 10:29am ET

A venture headed by hedge fund manager Dmitry Balyasny just paid $6.2 million for...

Guest Contributor

Hedge Funds Weather A Data Management Perfect Storm

Oct 22 2014 | 12:28pm ET

From a regulatory standpoint, nearly every development since the crisis has placed...

 

Videos

Editor's Note

    Guidelines for Guest Articles

    Oct 22 2014 | 9:46am ET

    We are always looking for guest articles from hedge fund managers and buy-side firms.

    If you are interested in submitting a contributed piece for possible publication on FINalternatives, please take a look at the specs. Read more…

 

Futures Magazine

October 2014 Cover

Deeply flawed risk benchmark

Most traders agree that proper risk management is the key to successful trading. However, many traders depend on the deeply flawed measure of standard deviation as a benchmark of risk. Here we put it ...

The Alpha Pages

TAP July/August 2014 Cover

The Alpha Pages Interview: Senator Rand Paul

Senator Paul sat down in the debut series of the Alpha Pages Interview to discuss the broken tax code, regulation surrounding Bitcoin, and his plans for the 2016 Presidential election.